Duloxetine-associated tachycardia

被引:13
作者
Stevens, Debra L. [1 ]
机构
[1] OKDHS Dev Disabil Serv, Div LOC 1353, Oklahoma City, OK 73125 USA
关键词
duloxetine; tachycarida;
D O I
10.1345/aph.1L108
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of symptomatic tachycardia that was successfully treated with proparnolol in a patient receiving duloxetine. CASE SUMMARY: A 26-year-old man presented with episodes of fatigue, tachycardia, diaphoresis, and chest pain approximately 2 months after the initiation of duloxetine 20 mg/day for dysthymic disorder. Cardiac workup including echocardiogram, exercise treadmill testing, and Holter monitoring was negative, except for tachycardia (heart rate 110-120 beats/min). Duloxetine was withheld, and the patient's heart rate returned to normal in less than a week. Duloxetine was restarted at the same dosage, and tachycardia returned within 2 days. Propranolol was added to the treatment regimen to lower the heart rate. Because of therapeutic failure of other antidepressants, deuloxetine was continued because of its beneficial effects on mood. DISCUSSION: One published case report describing tachycardia in association with duloxetine in 2 heart failure patients was found in a MEDLINE search (1966-July 2008). Increased blood pressure and heart rate have been reported in duloxetine trials. The proposed mechanism for duloxetine-induced tachycardia is its effects on norepinephrine, which impact the cardiovascular system. Use of the Naranjo probability scale indicated duloxetine as a probable cause of this patient's tachycardia. CONCLUSIONS: Clinicians should be aware of the possibility of clinically significant tachycardia in patients receiving duloxetine, even in low doses.
引用
收藏
页码:1511 / 1513
页数:3
相关论文
共 10 条
[1]   Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy [J].
Colucci, Vincent J. ;
Berry, Bradley D. .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (06) :882-887
[2]   The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate [J].
Derby, Michael A. ;
Zhang, Lu ;
Chappell, Jill C. ;
Gonzales, Celedon R. ;
Callaghan, J. T. ;
Leibowitz, Mark ;
Ereshefsky, Larry ;
Hoelscher, David ;
Leese, Philip T. ;
Mitchell, Malcolm I. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (06) :384-393
[3]  
DeVoe JE, 2007, J FAM PRACTICE, V56, P59
[4]  
*EL LILL COMP, 2007, PACK INS CYMB DUL
[5]   Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases [J].
Howell, C. ;
Wilson, A. D. ;
Waring, W. S. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (02) :192-197
[6]   Cardiovascular changes associated with venlafaxine in the treatment of late-life depression [J].
Johnson, Ellyn M. ;
Whyte, Ellen ;
Mulsant, Benoit H. ;
Pollock, Bruce G. ;
Weber, Elizabeth ;
Begley, Amy E. ;
Reynolds, Charles F. .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (09) :796-802
[7]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[8]   Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study [J].
Raskin, Joel ;
Wang, Fujun ;
Pritchett, Yili Lu ;
Goldstein, David J. .
PAIN MEDICINE, 2006, 7 (05) :373-385
[9]   Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine [J].
Thase, ME ;
Tran, PV ;
Wiltse, C ;
Pangallo, BA ;
Mallinckrodt, C ;
Detke, MJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (02) :132-140
[10]   An evaluation of the cardiovascular safety profile of duloxetine -: Findings from 42 placebo-controlled studies [J].
Wernicke, Joachim ;
Lledo, Alberto ;
Raskin, Joel ;
Kajdasz, Daniel K. ;
Wang, Fujun .
DRUG SAFETY, 2007, 30 (05) :437-455